Salman Arain
Endpoint critiqueInterventional cardiologist and fellowship program directorORBITA-CTO is not the ultimate CTO PCI trial, but it met its objective with adequate validity.
Original post ↗What happened
In patients with single-vessel CTO, CTO PCI improved the angina symptom score compared with a placebo procedure.
Salman Arain
Endpoint critiqueInterventional cardiologist and fellowship program directorORBITA-CTO is not the ultimate CTO PCI trial, but it met its objective with adequate validity.
Original post ↗Procedures like angioplasty can often have large placebo effects because patients are expecting to get better. Yet no previously published study of angioplasty for CTO had compared it with a placebo procedure.
ORBITA-CTO co-authorOur results demonstrate in a randomized, double-blinded study design that coronary angioplasty and stenting is an effective treatment for patients who have a chronic total occlusion and chronic anginal chest pain. These results provide hope for both patients with CTO and their doctors that angioplasty with stenting can be successful and can result in reduced angina pain and better quality of life.
ORBITA-CTO co-authorIf we want to know whether CTO PCI truly works, we must also test it under blinded conditions.
ORBITA-CTO co-authorIt proves that CTO PCI improves angina symptoms, which is immediate, sustained, and consistent. This supports symptom-driven PCI in carefully selected patients, through the heart team selection, in centers with specialist CTO operators.
ORBITA-CTO co-authorUntil today, we still had the unanswered question of what is the true placebo-adjusted benefit of CTO PCI.
ORBITA-CTOThese are patients with just a single-vessel CTO and no other significant coronary artery disease. The trial was very well conducted, obviously, just an incredible design, and they were meticulous in trying to adjust for all different confounding variables. My only comment would be the generalizability of the results. It's also a very selected group of operators as well.
ORBITA-CTOFor a field that has long relied on technical accomplishment as a surrogate for clinical effect, this kind of evidence is invaluable. …The next challenge for the field is to determine when, and for whom, it works best.
ORBITA-CTOUpvote a question you would like answered, or open it to join the discussion.
Answers are grounded in this paper and cite their sources.
Why the trial, tables, limitations, PICO, abstract, media & sources
Why the trial?
The ORBITA-CTO trial was conducted to address the lack of blinded randomized evidence on whether percutaneous coronary intervention (PCI) for coronary chronic total occlusion (CTO) improves symptoms and quality of life in patients with angina attributable to a single-vessel CTO.
Does CTO PCI improve angina symptoms in patients with stable angina attributable to a single-vessel CTO compared to a placebo procedure?
RCT (n=50)
Blinded
Randomized
Yes
Does CTO PCI improve angina symptoms in patients with stable angina attributable to a single-vessel CTO compared to a placebo procedure?
In the first placebo-controlled trial of CTO PCI, the procedure significantly improved angina symptoms and quality of life in patients with single-vessel CTO.
Experts read ORBITA-CTO as solid proof that opening a chronic total occlusion relieves angina beyond placebo, which supports offering the procedure to carefully selected patients with symptoms.
The reaction is uniformly positive. Interventional cardiologists see this as the first placebo-controlled evidence that the procedure helps symptoms, not just a technical success. Nobody disputes the result, but they agree it is not the final word, and the live question is which patients benefit most.
All three interventional cardiologists say the trial produced credible, valuable evidence that the procedure has a real clinical effect on symptoms, beyond technical success or placebo.
Ali says the field still has to work out when, and for whom, the procedure works best. Arain calls ORBITA-CTO definitely not the ultimate trial of CTO PCI. Davies limits the support to carefully selected patients treated by specialist operators.
Supports CTO PCI for symptom relief in single-vessel CTO; confirms benefit in first placebo-controlled RCT and strengthens Class IIa guidance.
BACKGROUND: Percutaneous coronary intervention for coronary chronic total occlusion (CTO PCI) is offered for symptom and quality of life improvement, despite the absence of blinded randomized evidence. OBJECTIVES: The aim of this study was to assess the efficacy of CTO PCI in the first randomized, placebo-controlled trial of CTO PCI. METHODS: ORBITA-CTO is a multicenter, randomized, blinded trial comparing CTO PCI with a placebo procedure. Patients had angina attributable to a single-vessel CTO, without bystander coronary disease. Angina symptoms were recorded daily using the ORBITA app. After dual-injection coronary angiography, patients were randomized to either CTO PCI or placebo. Blinding was maintained using auditory isolation and deep conscious sedation. Antianginal medications were stopped at randomization and reintroduced on a patient-initiated protocol. At the 6-month follow-up, assessments were repeated. The primary efficacy outcome was the angina symptom score, an ordinal scale combining the daily symptom burden assessed by the ORBITA app, antianginal use, and over-ride events. Secondary outcomes were symptom and quality of life questionnaires and blinding fidelity. RESULTS: Between October 19, 2021 and October 21, 2025, 50 patients were randomly assigned to CTO PCI (n = 25) or placebo (n = 25). One patient randomized to PCI was withdrawn during the procedure because of a complication. All 50 patients were included in the primary analysis. Compared with placebo, CTO PCI resulted in an immediate and sustained improvement in the angina symptom score (OR: 4.38; 95% credible interval [CrI]: 1.57-12.69; probability of benefit [Pr{Benefit}] = 0.996), arising from a clear reduction in the number of episodes of angina (OR: 4.38; 95% CrI: 1.55-11.78; Pr[Benefit] = 0.997). This resulted in an additional 30.6 days free of angina (95% CrI: 11.1-50.7; Pr[Benefit] >0.999). Improvements were also observed with the Seattle Angina Questionnaire in angina frequency (+10.7; 95% CrI: 1.4-20.2; Pr[Benefit] = 0.988), physical limitation, quality of life, and summary score and Canadian Cardiovascular Society class. Blinding of patients, staff, and researchers was maintained. CONCLUSIONS: In patients with symptomatic single-vessel CTO, CTO PCI improves angina beyond placebo. (A Placebo-controlled Trial of Chronic Total Occlusion Percutaneous Coronary Intervention for the Relief of Stable Angina [ORBITA-CTO]; NCT05142215).
Khan et al. (2026) conducted an RCT in Stable angina with single-vessel chronic total occlusion (n=50). Chronic Total Occlusion Percutaneous Coronary Intervention (CTO PCI) vs. Placebo procedure was evaluated on Angina symptom score (ordinal scale combining daily symptom burden, antianginal use, and over-ride events) (OR 4.38, 95% CI 1.57-12.69, p=Pr[Benefit] = 0.996). In patients with single-vessel CTO, CTO PCI improved the angina symptom score compared with a placebo procedure.
Synapse has enriched 10 related papers. Consider them for comparative context: